4.16Main Arena
4.14Live-Main Arena
4.15Live-Main Arena morning
4.15Live-Main Arena Afternoon
4.15Live-Baohina Meeting Room

Webcast-China Valve(Hang Zhou)

2017-04-14 13:30:00 ~ 2017-04-16 11:30:00

Webcast Introduction

Incidence of valvular heart diseases keeps increasing along with the aging trend of the world, and makes it a serious threat to human health. As the evidence accumulates, transcatheter valvular replacement or repair emerged as an alternative for traditional cardiac surgery, especially in the field of transcatheter aortic valve replacement (TAVR). However, development of transcatheter valvular treatment in China is still at the initial status. There is an urgent call for systemic training for Chinese interventional cardiologists and their heart valve teams. 
To improve transcatheter valvular treatment in China and international collaboration in the field, the third China Valve (Hangzhou) congress will be held on 14th to 16th April 2017. This year, we will continuously work with the support of CSI to provide a broader global vision, an improved training course and a deeper communicative platform. The program will include step by step learning from recorded cases, live cases, hands-on sessions, imaging training, up-to-date clinical trials and debates on hot spots, etc.
Hangzhou is an ancient, yet highly civilized city rich in both historical sites and natural landscapes, such as the West Lake and Grand Canal. The city is also an international metropolis where the G20 summit held in September 2016. You will have the opportunity to enjoy the wonderful scenery after scientific activities. 
Welcome to Hangzhou!
Program
Session 1: Learning from recorded TAVR case step by step
13:30-14:50  Main Arena
Chairpersons:Yan_WANG Ben_HE Jun_JIANG
Time
Speaker
Title
Comments
13:30-13:40
Xianbao_LIU
Clinical evaluation
13:40-13:50
Lei_YU
Echo Evaluation
13:50-14:00
Yuxin_HE
CT analysis
14:00-14:10
Jian’an_WANG Aiqiang_DONG Xianbao_LIU Wei_HE Zhaoxia_PU Yuxin_HE Jifang_CHENG
Heart valve team discussion (cardiologist, surgeon, anesthesiologist, radiologist, nurse)
14:10-14:30
Jian’an_WANG
Recorded TAVR case step by step
14:30-14:50
Discussion
14:50-15:00
Coffee and Tea Break
Session 2: Optimising TAVR outcomes
15:00-16:20  Main Arena
Chairpersons:Horst_SIEVERT Jian’an_Wang Yongjian_WU Qiang_WU Sung-Han_YOON Paul_CHIAM
Time
Speaker
Title
Comments
15:00-15:10
Eberhard_GRUBE
Optimiaing TAVR Outcomes:Where are the Limits
15:10-15:20
Mao_CHEN
TF-TAVR: How to evaluate and get vascular access safe
15:20-15:30
Yingqiang_GUO
TA-TAVR: Access evaluation and procedural consideration
15:30-15:40
Jian’an_WANG
Super Stiff wire and pre-dilation balloon selection and manipulation
15:40-15:50
Wei-Hsian_YIN
How to choose correct THV and valve size
15:50-16:00
Thomas_MODINE
Double S curve guided deployment
16:00-16:20
Discussion
16:20-16:40
Coffee and Tea Break
Session 3: Making TAVR simple
16:40-18:00  Main Arena
Chairpersons:Yong_HUO Mao_CHEN Wei-Hsian_YIN Atiq_REHMAN Norio_TADA Guangyuan_SONG
Time
Speaker
Title
Comments
16:40-16:50
Yung-Tsai_LEE
TTE or TEE guidance?
16:50-17:00
Duk-Woo_PARK
Local or general anesthesia?
17:00-17:10
Michael_Kang-Yin_LEE
Shall we skip balloon pre-dilation?
17:10-17:20
Yat-Yin_LAM
Hybrid or ordinary catheter room?
17:20-17:30
Yongjian_WU
Will TAVR be performed as PCI in the future?
17:30-17:40
Horst_SIEVERT
Will heart valve team be changed in the future?
17:40-18:00
Discussion
Session 4: Moving forward to lower risk patients
08:00-09:00  Main Arena
Chairpersons:Jian’an_WANG Bo_XU Khalil_FATTOUCH Anthony_WALTON Meixiang_XIANG Wenzhi_PAN
Time
Speaker
Title
Comments
08:00-08:10
Ulrich_GERCKENS
What’s the real difference between high risk and lower risk patients
08:10-08:20
Eberhard_GRUBE
The limitations of surgery in lower risk patients-perspectives from interventionalist
08:20-08:30
Jeng_WEI
The limitations of TAVR in lower risk patients-perspectives from surgeon
08:30-08:40
Junbo_GE
Latest evidence and limitations
08:40-09:00
Discussion
09:00-09:20
Opening ceremony
Session 5: Dialogues of TAVR between China and the world
09:30-10:30  Main Arena
Chairpersons: Junbo_GE Horst_SIEVERT
Panelists: Eberhard_GRUBE Shah_Hinan_AHMED Jeng_WEI Mao_CHEN Thomas_MODINE Sung-Han_YOON
Time
Speaker
Title
Comments
09:30-10:20
Topics including: 1. Current status of TAVR in China and in the world 2. Bicuspid aortic valve 3. Home-made devices4.Perspectives from cardiologists and surgeons
10:20-10:30
Junbo_GE
Summary
Session 6: Live cases
10:30-12:00  Main Arena
Chairpersons:Junbo_GE Eberhard_GRUBE Bo_XU Khalil_FATTOUCH Michael Kang-Yin_LEE Dongming_HOU Daxin_ZHOU
Time
Speaker
Title
Comments
10:30-11:30
Jian’an_WANG Xianbao_LIU
TAVR live case
11:30-12:00
Robert_GOOLEY
Recorded TAVR case
12:00-13:30
Lunch Break (in the meeting room)
Session 7: TAVR in Asia
12:15-13:20  Main Arena
Chairpersons: Eberhard_GRUBE Horst_SIEVERT Jian’an_WANG Prashant_VAIJYANATH Yujie_Zhou
Time
Speaker
Title
Comments
12:15-12:23
Junbo_GE
TAVR in Mainland, China
12:23-12:31
Jeng_WEI
TAVR in Taiwan, China
12:31-12:39
Michael_Kang-Yin_LEE
TAVR in Hong Kong, China
12:39-12:47
Norio_TADA
TAVR in Japan
12:47-12:55
Duk-Woo_PARK
TAVR in Korea
12:55-13:03
Paul_CHIAM
TAVR in Singapore
13:03-13:11
Prashant_VAIJYANATH
TAVR in India
13:11-13:20
Discussion
Session 8: How to design TAVR clinical studies and get published
13:30-14:30  Main Arena
Chairpersons:Shah_Hinan_AHMED Dongming_HOU Zuyi_YUAN Biao_XU Xianxian_ZHAO
Time
Speaker
Title
Comments
13:30-13:50
Dongming_HOU
TAVR clinical trial program: tips for design and implementation
13:50-14:10
Shah_Hinan_AHMED
Translating your research into a quality, peer-reviewed publication
14:10-14:30
Discussion
Session 9: Live cases
14:30-16:30  Main Arena
Chairpersons:Junbo_GE Jian’an_WANG Ulrich_GERCKENS Thomas_MODINE Anthony_WALTON Mao_CHEN Yat-Yin_LAM Norio_TADA Duk-Woo_PARK
Time
Speaker
Title
Comments
14:30-15:30
Horst_SIEVERT Xianbao_LIU
TAVR live case
15:30-16:30
Wei-Hsian_YIN
TAVR live case from Taiwan
16:30-16:50
Coffee and Tea Break
Session 10: Long term outcomes and bioprosthetic valve durability
16:50-18:00  Main Arena
Chairpersons:Prashant_VAIJYANATH Yundai_CHEN Ling_TAO Genshan_MA Hong_WU
Time
Speaker
Title
Comments
16:50-17:00
Junbo_GE
Controversies over TAVR bioprostheses deterioration
17:00-17:10
Khalil_FATTOUCH
Lessons from surgical experience
17:10-17:20
Anthony_WALTON
Subclinical thrombosis, leaflet thickening and anti-coagulation strategy
17:20-17:30
Horst_SIEVERT
TAV in TAV: current status and future
17:30-17:40
Atiq_REHMAN
TAVR for younger patients: my thinking
17:40-18:00
Discussion
TAVR for bicuspid aortic valve
13:30-15:30  Baohina Meeting Room
Chairpersons: Michael_Kang-Yin_LEE Ruiyan_ZHANG Paul_CHIAM Guangyuan_Song Yanqing_WU Xiang_MA
Time
Speaker
Title
Comments
13:30-13:40
Khalil_FATTOUCH
Anatomic characteristics and procedural considerations
13:40-13:50
Sung-Han_YOON
What guideline say and up-to-date outcomes of clinical studies
13:50-14:00
Norio_TADA
Advantages and disadvantages of different transcatheter heart valves
14:00-14:10
Jian’an_WANG
Sizing strategy and outcomes - experience from China
14:10-14:30
Discussion
14:30-14:40
Wenzhi_PAN
Case from Zhongshan Hospital
14:40-14:45
Discussion
14:45-14:55
Guangyuan_SONG
Case from Fuwai Hospital
14:55-15:00
Discussion
15:00-15:10
Yuan_FENG
Case from Huaxi Hospital
15:10-15:15
Discussion
15:15-15:25
Feng_GAO
Case from SAHZU
15:25-15:30
Discussion
International challenging TAVR cases
16:00-18:00  Baohina Meeting Room
Chairpersons:Robert_GOOLEY Yat-Yin_LAM Duk-Woo_PARK Daxin_ZHOU Yuan_FENG Zhenfei_FANG
Time
Speaker
Title
Comments
16:00-16:10
Anthony_WALTON
Case from Australia
16:10-16:15
Discussion
16:15-16:25
Atiq_REHMAN
Case from United States
16:25-16:30
Discussion
16:30-16:40
Zhengbin_ZHU
Case from Shanghai, China
16:40-16:45
Discussion
16:45-16:55
Duk-Woo_PARK
Case from Korea
16:55-17:00
Discussion
17:00-17:10
Chia-Pin_LIN
Case from Taiwai, China
17:10-17:15
Discussion
17:15-17:25
Prashant_VAIJYANATH
Case from India
17:25-17:30
Discussion
17:30-17:40
Paul_CHIAM
Case from Singapore
17:40-17:45
Discussion
17:45-17:55
Xianbao_LIU
Case from Hangzhou, China
17:55-18:00
Discussion
Session 11: Management of complications-1
08:00-09:30  Main Arena
Chairpersons:Jian’an_WANG Robert_GOOLEY Yuan_FENG Xiang_MA Xianhe_LIN Xianbao_LIU
Time
Speaker
Title
Comments
08:00-08:10
Fei_LI
Case1: PVL
08:10-08:20
Daxin_ZHOU
How to prevent and treat PVL
08:20-08:30
Discussion
08:30-08:40
Moyang_WANG
Case2: Vascular complication
08:40-08:50
Thomas_MODINE
How to prevent and treat vascular complications
08:50-09:00
Discussion
09:00-09:10
Wenzhi_PAN
Case3: Conduction disturbance
09:10-09:20
Ulrich_GERCKENS
Predictors of conduction disturbance and how to minimize PPM
09:20-09:30
Discussion
09:30-09:40
Coffee and Tea Break
Session 12: Management of complications-2
09:40-11:10  Main Arena
Chairpersons:Ulrich_GERCKENS Ruiyan_ZHANG Heng_ZHANG Guoqing_LI Moyang_WANG
Time
Speaker
Title
Comments
09:40-09:50
Yuxin_HE
Case 4: Stroke
09:50-10:00
Robert_GOOLEY
Predictors and prevention of stroke
10:00-10:10
Discussion
10:10-10:20
Yuan_FENG
Case 5: Coronary obstruction
10:20-10:30
Jian’an_WANG
How to prevent and treat coronary obstructions
10:30-10:40
Discussion
10:40-10:50
Changfu_LIU
Case6: Annulus rupture
10:50-11:00
Sung-Han_YOON
How to prevent and treat annulus rupture or myocardial perforation
11:00-11:10
Discussion
Closing ceremony
11:20-11:30  Main Arena
Chairpersons:Jian’an_WANG
Time
Speaker
Title
Comments
11:20-11:30
Jian’an_WANG
Closing ceremony

Interaction

发送
欢迎在线互动